The Quantellect read.As of Nov 19, 2026, 7 active firms cover Tarsus Pharmaceuticals Inc: 7 rate it Buy or better, 0 sit at Neutral, and 0 rate it Sell or worse, a buy consensus. Targets are tightly clustered, $88.00 to $116.00, so the covering firms are broadly aligned. The average target of $100.86 sits 33% above the current $75.95. The rating mix has stayed broadly stable, with Buy-side ratings edging up from 5 to 7 over recent months. On the fundamentals, the Street sees consensus EPS building from about $-0.62 next quarter toward $0.21 the year after.Descriptive synthesis of third-party analyst data, not a Quantellect rating or recommendation.
ANALYST CONSENSUS7 active firms
Buy
Strong Buy00%
Buy7100%
Neutral00%
Sell00%
Strong Sell00%
Based on 7 active firms as of Nov 19, 2026 (365-day activity window).
12-MONTH PRICE TARGET
$100.86
+32.8% upside
Average target across 7 active firms as of Nov 19, 2026 vs $75.95 current
Highest Target$116.00
Average Target$100.86
Lowest Target$88.00
Detailed analyst forecasts for TARS
Showing 1–8 of 8 named analysts shown · 7 active firms in the rating projection
As of Nov 19, 2026, 7 of 7 active firms rate TARS a Buy (0 Neutral, 0 Sell). Historical months are month-end active-firm counts; the current month uses its actual as-of date.
TARS EPS & revenue forecast
EPS · NEXT QUARTER
$-0.62
Range $-0.65 – $-0.59 · 2 analysts · +288% YoY
Next period, 2 analysts expect Tarsus Pharmaceuticals Inc to earn $-0.62 a share (range $-0.65 – $-0.59), versus $-0.16 a year earlier. Full-year consensus is $-15.32, growing to $0.21 the year after.
REVENUE · NEXT QUARTER
$201.7M
Range $190.0M – $205.8M · 2 analysts · +24% YoY
Revenue is expected to reach $201.7M (range $190.0M – $205.8M), +24.5% year-over-year. Full-year consensus is $741.5M, rising to $942.1M next year.
Top analysts covering Tarsus Pharmaceuticals Inc
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on TARS.
#1
MC
Matthew Caufield
HC Wainwright & Co. · Rank #155
Buy
$88.00+15.9% to target
Overall win rate
49%
+ Follow
#2
Jason Gerberry
B of A Securities · Rank #160
Buy
$89.00+17.2% to target
Overall win rate
47%
+ Follow
#3
Oren Livnat
HC Wainwright & Co. · Rank #217
Buy
$73.00-3.9% to target
Overall win rate
54%
+ Follow
#4
Balaji Prasad
Barclays · Rank #226
Buy
$60.00-21.0% to target
Overall win rate
45%
+ Follow
#5
Graig Suvannavejh
Mizuho · Rank #239
Buy
$94.00+23.8% to target
Overall win rate
40%
+ Follow
TARS stock forecast FAQ
What is TARS's average 12-month price target?+
The 7 active firms with a live target average $100.86 for Tarsus Pharmaceuticals Inc over the next 12 months, ranging from a $116.00 high to a $88.00 low, as of Nov 19, 2026.
Is TARS stock a Buy, Sell or Neutral right now?+
The current consensus is Buy. Of the 7 active firms as of Nov 19, 2026, 7 rate it Buy or Strong Buy, 0 rate it Neutral, and 0 rate it Sell or Strong Sell.
What are the highest and lowest price targets for TARS?+
The Street-high target is $116.00 (Goldman Sachs), and the Street-low is $88.00 (HC Wainwright & Co.). The average of all 7 active-firm targets is $100.86.
How many active Wall Street firms cover TARS?+
7 active firms have a recognized rating on Tarsus Pharmaceuticals Inc as of Nov 19, 2026, and 7 active firms carry a live 12-month price target.
Who is the most accurate analyst covering TARS?+
Among analysts who currently cover TARS, Matthew Caufield of HC Wainwright & Co. has the strongest overall Quantellect track record (Rank #155). Their current call is Buy with a $88.00 target.
What is Tarsus Pharmaceuticals Inc's projected EPS for next quarter?+
The consensus estimate is $-0.62 per share (range $-0.65 – $-0.59) across 2 analysts. Full-year EPS is projected at $-15.32, rising to $0.21 the following year.
How much revenue is Tarsus Pharmaceuticals Inc expected to report next quarter?+
Consensus revenue is $201.7M (range $190.0M – $205.8M). Full-year revenue is projected at $741.5M, growing to $942.1M next year.
Have analysts been upgrading or downgrading TARS lately?+
As of Nov 19, 2026, 7 of 7 active firms rate TARS a Buy (0 Neutral, 0 Sell). Historical months are month-end active-firm counts; the current month uses its actual as-of date.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their TARS calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.